Gaining Insights Into Metabolic Networks Using Chemometrics and Bioinformatics: Chronic Kidney Disease as a Clinical Model.

bioinformatics chemometrics chronic kidney disease integrative data analysis metabolic networks metabolomics

Journal

Frontiers in molecular biosciences
ISSN: 2296-889X
Titre abrégé: Front Mol Biosci
Pays: Switzerland
ID NLM: 101653173

Informations de publication

Date de publication:
2021
Historique:
received: 18 03 2021
accepted: 19 04 2021
entrez: 31 5 2021
pubmed: 1 6 2021
medline: 1 6 2021
Statut: epublish

Résumé

Because of its ability to generate biological hypotheses, metabolomics offers an innovative and promising approach in many fields, including clinical research. However, collecting specimens in this setting can be difficult to standardize, especially when groups of patients with different degrees of disease severity are considered. In addition, despite major technological advances, it remains challenging to measure all the compounds defining the metabolic network of a biological system. In this context, the characterization of samples based on several analytical setups is now recognized as an efficient strategy to improve the coverage of metabolic complexity. For this purpose, chemometrics proposes efficient methods to reduce the dimensionality of these complex datasets spread over several matrices, allowing the integration of different sources or structures of metabolic information. Bioinformatics databases and query tools designed to describe and explore metabolic network models offer extremely useful solutions for the contextualization of potential biomarker subsets, enabling mechanistic hypotheses to be considered rather than simple associations. In this study, network principal component analysis was used to investigate samples collected from three cohorts of patients including multiple stages of chronic kidney disease. Metabolic profiles were measured using a combination of four analytical setups involving different separation modes in liquid chromatography coupled to high resolution mass spectrometry. Based on the chemometric model, specific patterns of metabolites, such as N-acetyl amino acids, could be associated with the different subgroups of patients. Further investigation of the metabolic signatures carried out using genome-scale network modeling confirmed both tryptophan metabolism and nucleotide interconversion as relevant pathways potentially associated with disease severity. Metabolic modules composed of chemically adjacent or close compounds of biological relevance were further investigated using carbon transfer reaction paths. Overall, the proposed integrative data analysis strategy allowed deeper insights into the metabolic routes associated with different groups of patients to be gained. Because of their complementary role in the knowledge discovery process, the association of chemometrics and bioinformatics in a common workflow is therefore shown as an efficient methodology to gain meaningful insights in a clinical context.

Identifiants

pubmed: 34055893
doi: 10.3389/fmolb.2021.682559
pmc: PMC8163225
doi:

Types de publication

Journal Article

Langues

eng

Pagination

682559

Informations de copyright

Copyright © 2021 Boccard, Schvartz, Codesido, Hanafi, Gagnebin, Ponte, Jourdan and Rudaz.

Déclaration de conflit d'intérêts

The authors declare that this study received indirect partial funding from AstraZeneca. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Références

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 May 15;1116:9-18
pubmed: 30951967
Bioinformatics. 2018 Jan 15;34(2):312-313
pubmed: 28968733
Bioinformatics. 2016 Jul 1;32(13):2065-6
pubmed: 27153692
Clin Lab Med. 1993 Mar;13(1):33-52
pubmed: 8462268
Nat Biotechnol. 2013 May;31(5):419-25
pubmed: 23455439
Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F671-F681
pubmed: 27413196
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W132-7
pubmed: 20444866
Anal Chim Acta. 2020 Feb 22;1099:26-38
pubmed: 31986274
Nat Biotechnol. 2018 Mar;36(3):272-281
pubmed: 29457794
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Nat Clin Pract Endocrinol Metab. 2008 Aug;4(8):444-52
pubmed: 18607402
Comput Struct Biotechnol J. 2013 Feb 06;4:e201301003
pubmed: 24688685
Metabolomics. 2018;14(6):72
pubmed: 29805336
Kidney Int. 2017 Jan;91(1):61-69
pubmed: 27692817
Bioinformatics. 2017 Feb 15;33(4):605-607
pubmed: 27993782
Bioinformatics. 2020 Nov 09;:
pubmed: 33165510
Nat Rev Nephrol. 2017 May;13(5):269-284
pubmed: 28262773
J Mol Biol. 2006 Feb 10;356(1):222-36
pubmed: 16337962
Nature. 2005 Feb 24;433(7028):895-900
pubmed: 15729348
Am J Nephrol. 1994;14(3):207-12
pubmed: 7977482
J Chromatogr A. 2019 May 10;1592:47-54
pubmed: 30685186
Nat Med. 2015 Jan;21(1):37-46
pubmed: 25419705
Clin Chim Acta. 2013 Jun 25;422:59-69
pubmed: 23570820
Brief Bioinform. 2017 Jan;18(1):43-56
pubmed: 26822099
Curr Opin Chem Biol. 2017 Feb;36:32-39
pubmed: 28088694
IEEE/ACM Trans Comput Biol Bioinform. 2008 Oct-Dec;5(4):594-617
pubmed: 18989046
J Am Soc Nephrol. 2016 Apr;27(4):1175-88
pubmed: 26449609
Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S4-12
pubmed: 12751049
Nucleic Acids Res. 2018 Jul 2;46(W1):W495-W502
pubmed: 29718355
Anal Chim Acta. 2020 Apr 8;1105:28-44
pubmed: 32138924
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Nephrol Dial Transplant. 2009 Jun;24(6):1901-8
pubmed: 19155537
Metabolomics. 2015;11(6):1667-1678
pubmed: 26491420
Bioinformatics. 2011 Jul 1;27(13):1878-9
pubmed: 21551139
Nucleic Acids Res. 2016 Jan 4;44(D1):D471-80
pubmed: 26527732
Curr Opin Microbiol. 2004 Jun;7(3):296-307
pubmed: 15196499
J Sep Sci. 2010 Feb;33(3):290-304
pubmed: 20087872
BMC Bioinformatics. 2018 Jan 02;19(1):1
pubmed: 29291722
Anal Chim Acta. 2017 Feb 22;955:27-35
pubmed: 28088278
Sci Rep. 2020 Nov 11;10(1):19502
pubmed: 33177589
Kidney Int. 2020 Jun;97(6):1117-1129
pubmed: 32409237
Metabolites. 2018 Sep 15;8(3):
pubmed: 30223552

Auteurs

Julien Boccard (J)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Domitille Schvartz (D)

Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland.

Santiago Codesido (S)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Mohamed Hanafi (M)

Unité Statistique, Sensométrie et Chimiométrie, Nantes, France.

Yoric Gagnebin (Y)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Belén Ponte (B)

Service of Nephrology and Hypertension, Department of Medicine, Geneva University Hospitals (HUG), Geneva, Switzerland.

Fabien Jourdan (F)

Toxalim, Research Centre in Food Toxicology, Université de Toulouse, INRAE, ENVT, INP-Purpan, UPS, Toulouse, France.

Serge Rudaz (S)

School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.

Classifications MeSH